Who backs 858 Therapeutics?
8 investors| Investor | Type |
|---|---|
| Insight Partners (New York) | PE / buyout |
| New Enterprise Associates | Venture capital |
| Alexandria Venture Investments | Other |
| Mirae Asset Capital | Venture capital |
| Cormorant Asset Management | Venture capital |
| Logos Capital | Hedge fund |
| Avidity Partners | Asset manager |
| Versant Ventures | Venture capital |
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns
Membership and data by Private Market View
858 Therapeutics investors
8 investors are on record for 858 Therapeutics, including Insight Partners (New York), New Enterprise Associates, Alexandria Venture Investments and Mirae Asset Capital. By type, the record holds 4 venture capital firms, 1 hedge fund and 1 asset manager. The early-stage round in Jun 2024 drew 12 investors.
Free account
More of 858 Therapeutics with a free account
- ·Watch 858 Therapeutics: the Monday email on marks, rounds and moves
For fundraisers
Work this list, don’t just read it
These 8 firms already write checks for companies like 858 Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.
Membership and data by Private Market View